Taken together, these results demonstrate that the therapeutic efficacy of PARP and WEE1 inhibitors can be further potentiated with the addition of STING agonist and anti-PD-1 to induce complete tumour clearance and improve survival outcomes in BRCA1/2 wild-type TNBC with moderate levels of pre-existing TILs. This evidence concerns the gene BRCA1 and neoplasm.